New antipsychotics

Here are some new antipsychotics that have been approved or are in development:

  1. Lurasidone (Latuda): Approved in 2009, lurasidone is a second-generation antipsychotic that is used to treat schizophrenia and bipolar disorder. It has a unique mechanism of action and is known for its relatively low risk of extrapyramidal symptoms (EPS) and weight gain.
  2. Asenapine (Saphris): Approved in 2009, asenapine is a second-generation antipsychotic that is used to treat schizophrenia and bipolar disorder. It is a sublingual tablet that is placed under the tongue to dissolve and is known for its rapid onset of action.
  3. Paliperidone (Invega): Approved in 2006, paliperidone is a second-generation antipsychotic that is used to treat schizophrenia. It is an extended-release tablet that is designed to provide a steady release of the medication over several days.
  4. Risperidone (Risperdal): Approved in 1994, risperidone is a second-generation antipsychotic that is used to treat schizophrenia and bipolar disorder. It is known for its effectiveness in treating symptoms of psychosis, such as hallucinations and delusions.
  5. Aripiprazole (Abilify): Approved in 2002, aripiprazole is a second-generation antipsychotic that is used to treat schizophrenia, bipolar disorder, and major depressive disorder. It is known for its relatively low risk of EPS and weight gain.
  6. Cariprazine (Vraylar): Approved in 2015, cariprazine is a third-generation antipsychotic that is used to treat schizophrenia and bipolar disorder. It is known for its unique mechanism of action and is designed to target the dopamine D3 receptor.
  7. Pimavanserin (Nuplazid): Approved in 2016, pimavanserin is a third-generation antipsychotic that is used to treat hallucinations and delusions associated with Parkinson's disease psychosis. It is known for its relatively low risk of EPS and is designed to target the serotonin 5-HT2A receptor.
  8. Iloperidone (Fanapt): Approved in 2009, iloperidone is a second-generation antipsychotic that is used to treat schizophrenia. It is known for its relatively low risk of EPS and is designed to target the dopamine D2 receptor.
  9. Ziprasidone (Geodon): Approved in 2001, ziprasidone is a second-generation antipsychotic that is used to treat schizophrenia and bipolar disorder. It is known for its relatively low risk of EPS and is designed to target the dopamine D2 receptor.
  10. Brexpiprazole (Rexulti): Approved in 2015, brexpiprazole is a second-generation antipsychotic that is used to treat schizophrenia and major depressive disorder. It is known for its relatively low risk of EPS and is designed to target the dopamine D2 receptor.

New antipsychotics in development:

  1. ADX-4867: A third-generation antipsychotic that is being developed by Adnexus Therapeutics to treat schizophrenia and bipolar disorder.
  2. BAN2401: A third-generation antipsychotic that is being developed by Biogen to treat schizophrenia and bipolar disorder.
  3. CERC-301: A third-generation antipsychotic that is being developed by Cerecor to treat schizophrenia and bipolar disorder.
  4. GSK-2334470: A third-generation antipsychotic that is being developed by GlaxoSmithKline to treat schizophrenia and bipolar disorder.
  5. Lamotrigine ER: A third-generation antipsychotic that is being developed by GlaxoSmithKline to treat bipolar disorder.

Note: This is not an exhaustive list, and new antipsychotics are being developed and approved regularly.